NOX2, oxidative stress, and overactive brain networks in Alzheimer's
Exploring NOX2-Mediated Network Impairment and Neurodegeneration in Alzheimer's Disease
['FUNDING_R01'] · J. DAVID GLADSTONE INSTITUTES · NIH-11241118
Researchers are looking into whether a molecule called NOX2 causes oxidative stress, reduced brain glucose use, and overactive brain networks that may speed memory loss in people with Alzheimer's.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | J. DAVID GLADSTONE INSTITUTES (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11241118 on ClinicalTrials.gov |
What this research studies
This project explores how NOX2-driven oxidative stress may lead to reduced glucose use in the brain and to network overactivity linked with Aβ and Tau buildup. Scientists will use laboratory models together with human-relevant biomarker and clinical data to map how NOX2 activation leads to seizures, network dysfunction, and neuron damage. They will test whether blocking NOX2 activity or calming network hyperactivity can protect neurons and preserve cognitive function. The goal is to connect molecular damage to measurable brain changes that could become targets for early intervention in Alzheimer's.
Who could benefit from this research
Good fit: Ideal candidates would be people with early-stage Alzheimer's disease or mild cognitive impairment related to AD who are willing to provide clinical information, participate in biomarker studies, or be considered for future related trials.
Not a fit: People without AD or those with very advanced dementia who cannot benefit from early-intervention strategies are unlikely to gain direct benefit from this work.
Why it matters
Potential benefit: If successful, this work could point to new ways to reduce oxidative stress and brain overactivity and potentially slow cognitive decline in people with Alzheimer's.
How similar studies have performed: Previous work showed that reducing hippocampal hyperactivity with the drug levetiracetam improved cognition in amnestic MCI patients and animal models, while targeting NOX2 itself is a newer and more mechanistic approach.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- J. DAVID GLADSTONE INSTITUTES — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZILBERTER, MISHA YURI — J. DAVID GLADSTONE INSTITUTES
- Study coordinator: ZILBERTER, MISHA YURI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia